StockNews.com Downgrades Abeona Therapeutics to Sell

Abeona Therapeutics (NASDAQ:ABEO) has been downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating, as presented in a recent research report issued on Saturday.

Other analysts have also commented on Abeona Therapeutics in their reports. For instance, Cantor Fitzgerald maintained an "overweight" rating on the stock and set a target price of $18.00 on October 29th. Meanwhile, HC Wainwright reaffirmed a "buy" rating with a target price of $15.00 on Wednesday.

Abeona Therapeutics Stock Performance

On Friday, shares of Abeona Therapeutics opened at $5.78. The company reports a quick ratio of 6.12, a current ratio of 6.12, and a debt-to-equity ratio of 0.31. The 50-day moving average price stands at $5.65, while the two-hundred day moving average price is $5.81. The stock has experienced a 52-week low of $3.05 and a high of $9.01. The company has a market capitalization of $251.26 million, a P/E ratio of -2.15, and a beta value of 1.43.

Institutional Investors Weigh In On Abeona Therapeutics

In recent times, several hedge funds have altered their positions in Abeona Therapeutics. For example, abrdn plc increased its holdings in the company by 158.8% during the third quarter, bringing its total to 326,995 shares valued at $2,067,000 after acquiring 200,647 additional shares. Rosalind Advisors Inc. also raised its stake by 4.7%, now owning 1,832,000 shares worth $11,578,000 after purchasing 82,000 extra shares. GSA Capital Partners LLP boosted its holdings by 54.3%, owning 96,092 shares valued at $607,000, after buying 33,831 additional shares.

Moreover, Charles Schwab Investment Management Inc. acquired a new stake in Abeona Therapeutics in the same quarter valued at approximately $151,000. Citigroup Inc. upped its holdings in the biopharmaceutical company by 10.1%, now owning 616,668 shares worth $3,897,000 after an additional purchase of 56,332 shares. Overall, institutional investors now control 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapy products intended for severe and life-threatening rare diseases. The company's leading programs include EB-101, gene-corrected skin grafts for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which consists of AAV-based gene therapies for Sanfilippo syndrome type A; and ABO-101, designed as adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Should You Invest $1,000 in Abeona Therapeutics Right Now?

Before considering an investment in Abeona Therapeutics, investors might want to note important insights.

Analyzed by market experts, Abeona Therapeutics has received a “Buy” rating. However, several top-rated analysts advocate for other stock options that may present better investment opportunities.

Abeona, Therapeutics, Stock